André Ulmann and Arnold Newman have joined forces as co-founders of Nulyn Science. The transatlantic partnership is focused on improving health outcomes by developing and expanding access to innovative treatments. By focusing their efforts on drug repurposing and international licensing, Nulyn Science intends to significantly reduce the time, cost, and risk of development for its products.
The team is initially focused on advancing its first two candidates through regulatory proceedings and securing additional funds for future trials. Both candidates, NS-001 and NS-002, have shown positive results in pre-clinical and clinical data and have long safety records, bolstering the Nulyn Team’s confidence in the success of its initial pipeline.
Nulyn Science’s founders bring over 60 years of success as entrepreneurs and pharmaceutical executives. André Ulmann, MD is the founder and former CEO of HRA pharma where he successfully developed the first 'morning after pill’. While Arnold Newman is a veteran of the Johns Hopkins Applied Physics lab where he helped develop the first implantable defibrillator and other medical devices before going on to found several successful companies.
If you’d like to learn more about the work at Nulyn Science, please contact us at hello@nulynscience.com.
